Neuroendocrine tumors: current recommendations for diagnosis and surgical management.

[1]  E. Woltering,et al.  Lymphatic mapping helps to define resection margins for midgut carcinoids. , 2009, Surgery.

[2]  C. Schade-Brittinger,et al.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Öberg.  Is It Time to Widen the Use of Somatostatin Analogs in Neuroendocrine Tumors , 2009 .

[4]  M. Idrees,et al.  In Vitro Chemoresistance Testing in Well-Differentiated Carcinoid Tumors , 2009, Annals of Surgical Oncology.

[5]  G. Kaltsas,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations , 2008, Neuroendocrinology.

[6]  G. Kaltsas,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biotherapy , 2008, Neuroendocrinology.

[7]  G. Mamikunian,et al.  Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients , 2008, Pancreas.

[8]  E. Nakakura,et al.  Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer? , 2007, Surgical oncology clinics of North America.

[9]  R. Valkema,et al.  Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. , 2007, Hematology/oncology clinics of North America.

[10]  K. Stuart,et al.  Liver-directed therapies for metastatic neuroendocrine tumors. , 2007, Hematology/oncology clinics of North America.

[11]  B. Diggs,et al.  Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. , 2006, Surgery.

[12]  G. Mamikunian,et al.  Validation of Serum Versus Plasma Measurements of Chromogranin A Levels in Patients With Carcinoid Tumors: Lack of Correlation Between Absolute Chromogranin A Levels and Symptom Frequency , 2006, Pancreas.

[13]  T. Fojo,et al.  Treatment of metastatic disease in patients with neuroendocrine tumors. , 2006, Surgical oncology clinics of North America.

[14]  G. Mamikunian,et al.  Effect of Octreotide LAR Dose and Weight on Octreotide Blood Levels in Patients With Neuroendocrine Tumors , 2005, Pancreas.

[15]  J. Norton.  Surgical treatment of neuroendocrine metastases , 2005 .

[16]  J. Keller,et al.  Human pancreatic exocrine response to nutrients in health and disease , 2005, Gut.

[17]  D. Breen,et al.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) , 2005, Gut.

[18]  M. Holzman,et al.  Surgical Treatment of Advanced-Stage Carcinoid Tumors: Lessons Learned , 2005, Annals of surgery.

[19]  R. Sutton,et al.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours , 2005, Gut.

[20]  E. Krenning,et al.  Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Wiedenmann,et al.  Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours , 2004, Neuroendocrinology.

[22]  M. Vatn,et al.  Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms) Part II—Specific NE Tumour Types , 2004, Acta oncologica.

[23]  P. Ruszniewski,et al.  Chemotherapy for Gastro-Enteropancreatic Endocrine Tumours , 2004, Neuroendocrinology.

[24]  K. Öberg.  Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms) , 2004 .

[25]  G. Klöppel,et al.  The Gastroenteropancreatic Neuroendocrine Cell System and Its Tumors: The WHO Classification , 2004, Annals of the New York Academy of Sciences.

[26]  K. Horton,et al.  Carcinoid tumors of the small bowel: a multitechnique imaging approach. , 2004, AJR. American journal of roentgenology.

[27]  K. Calhoun,et al.  Serum peptide profiles in patients with carcinoid tumors. , 2003, American journal of surgery.

[28]  B. Ahrén,et al.  Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumours , 2003, The British journal of surgery.

[29]  G. Åkerström,et al.  Effect of Surgery on the Outcome of Midgut Carcinoid Disease with Lymph Node and Liver Metastases , 2002, World Journal of Surgery.

[30]  A. Louie,et al.  Prospective study of the antitumor efficacy of long‐term octreotide treatment in patients with progressive metastatic gastrinoma , 2002, Cancer.

[31]  L. Kvols,et al.  A Phase II study of high‐dose paclitaxel in patients with advanced neuroendocrine tumors , 2001, Cancer.

[32]  R. Jian,et al.  The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors , 2000, American Journal of Gastroenterology.

[33]  D. Coursin,et al.  Perioperative Management of Selected Endocrine Disorders , 2000, International anesthesiology clinics.

[34]  A. Kurosky,et al.  Prohormone convertase-1 is essential for conversion of chromogranin A to pancreastatin , 1999, Regulatory Peptides.

[35]  E. Krenning,et al.  Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. , 1997, The Journal of clinical endocrinology and metabolism.

[36]  U. Tylén,et al.  Treatment of Liver Metastases of Carcinoid Tumors , 1996, World Journal of Surgery.

[37]  K. Öberg.  Treatment of neuroendocrine tumors. , 1994, Cancer treatment reviews.

[38]  E. Woltering,et al.  Long-term efficacy of octreotide in the treatment of Zollinger-Ellison syndrome. , 1992, Archives of surgery.

[39]  E. Woltering,et al.  Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison syndrome. , 1990, Surgery, gynecology & obstetrics.

[40]  J. Godwin.  Carcinoid Tumors An analysis of 2837 cases , 1975, Cancer.

[41]  S. Carter,et al.  Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. , 1973, Annals of internal medicine.

[42]  K. Öberg.  Chemotherapy and biotherapy in the treatment of neuroendocrine tumours , 2001 .

[43]  E. Woltering,et al.  Effect of a somatostatin analog (octreotide acetate) on the growth of retinal pigment epithelial cells in culture. , 1996, Current eye research.

[44]  K. Batts,et al.  Hepatic resection for metastatic neuroendocrine carcinomas. , 1995, American journal of surgery.